' Акцијски курс '

Datum	Amicus Therapeutics Cena akcije
20. 12. 2024.	10,03 undefined
20. 12. 2024.	9,80 undefined
19. 12. 2024.	9,73 undefined
18. 12. 2024.	9,57 undefined
17. 12. 2024.	9,89 undefined
16. 12. 2024.	9,90 undefined
13. 12. 2024.	9,36 undefined
12. 12. 2024.	10,15 undefined
11. 12. 2024.	10,16 undefined
10. 12. 2024.	10,13 undefined
9. 12. 2024.	9,83 undefined
6. 12. 2024.	9,73 undefined
5. 12. 2024.	9,76 undefined
4. 12. 2024.	9,86 undefined
3. 12. 2024.	9,79 undefined
2. 12. 2024.	9,96 undefined
29. 11. 2024.	9,99 undefined
27. 11. 2024.	9,96 undefined
26. 11. 2024.	9,87 undefined
25. 11. 2024.	9,72 undefined
22. 11. 2024.	9,66 undefined

Datum	Amicus Therapeutics Promet	Amicus Therapeutics EBIT	Amicus Therapeutics Profit
2030e	1,28 milijardi undefined	829,46 mil. undefined	670,53 mil. undefined
2029e	1,39 milijardi undefined	735,56 mil. undefined	838,16 mil. undefined
2028e	1,20 milijardi undefined	574,12 mil. undefined	547,09 mil. undefined
2027e	980,76 mil. undefined	421,02 mil. undefined	330,17 mil. undefined
2026e	809,63 mil. undefined	221,43 mil. undefined	154,13 mil. undefined
2025e	652,85 mil. undefined	107,33 mil. undefined	44,50 mil. undefined
2024e	536,46 mil. undefined	28,12 mil. undefined	-60,65 mil. undefined
2023	399,36 mil. undefined	-76,08 mil. undefined	-151,58 mil. undefined
2022	329,20 mil. undefined	-205,50 mil. undefined	-236,60 mil. undefined
2021	305,50 mil. undefined	-206,40 mil. undefined	-250,50 mil. undefined
2020	260,90 mil. undefined	-247,00 mil. undefined	-276,90 mil. undefined
2019	182,20 mil. undefined	-304,10 mil. undefined	-356,40 mil. undefined
2018	91,20 mil. undefined	-328,80 mil. undefined	-349,00 mil. undefined
2017	36,90 mil. undefined	23,40 mil. undefined	-284,00 mil. undefined
2016	5,00 mil. undefined	-181,80 mil. undefined	-200,00 mil. undefined
2015	0 undefined	-130,40 mil. undefined	-132,10 mil. undefined
2014	1,20 mil. undefined	-68,80 mil. undefined	-68,90 mil. undefined
2013	400.000,00 undefined	-61,70 mil. undefined	-59,60 mil. undefined
2012	18,40 mil. undefined	-52,90 mil. undefined	-48,80 mil. undefined
2011	21,40 mil. undefined	-50,90 mil. undefined	-44,40 mil. undefined
2010	900.000,00 undefined	-55,80 mil. undefined	-54,90 mil. undefined
2009	64,40 mil. undefined	-5,90 mil. undefined	-6,60 mil. undefined
2008	15,00 mil. undefined	-44,00 mil. undefined	-39,40 mil. undefined
2007	1,80 mil. undefined	-45,80 mil. undefined	-41,50 mil. undefined
2006	0 undefined	-46,90 mil. undefined	-65,90 mil. undefined
2005	0 undefined	-20,80 mil. undefined	-20,10 mil. undefined
2004	0 undefined	-8,50 mil. undefined	-8,90 mil. undefined

	Promet	EBIT	Profit
2004	0 USD	-8,50 mil. USD	-8,90 mil. USD
2005	0 USD	-20,80 mil. USD	-20,10 mil. USD
2006	0 USD	-46,90 mil. USD	-65,90 mil. USD
2007	1,80 mil. USD	-45,80 mil. USD	-41,50 mil. USD
2008	15,00 mil. USD	-44,00 mil. USD	-39,40 mil. USD
2009	64,40 mil. USD	-5,90 mil. USD	-6,60 mil. USD
2010	900.000,00 USD	-55,80 mil. USD	-54,90 mil. USD
2011	21,40 mil. USD	-50,90 mil. USD	-44,40 mil. USD
2012	18,40 mil. USD	-52,90 mil. USD	-48,80 mil. USD
2013	400.000,00 USD	-61,70 mil. USD	-59,60 mil. USD
2014	1,20 mil. USD	-68,80 mil. USD	-68,90 mil. USD
2015	0 USD	-130,40 mil. USD	-132,10 mil. USD
2016	5,00 mil. USD	-181,80 mil. USD	-200,00 mil. USD
2017	36,90 mil. USD	23,40 mil. USD	-284,00 mil. USD
2018	91,20 mil. USD	-328,80 mil. USD	-349,00 mil. USD
2019	182,20 mil. USD	-304,10 mil. USD	-356,40 mil. USD
2020	260,90 mil. USD	-247,00 mil. USD	-276,90 mil. USD
2021	305,50 mil. USD	-206,40 mil. USD	-250,50 mil. USD
2022	329,20 mil. USD	-205,50 mil. USD	-236,60 mil. USD
2023	399,36 mil. USD	-76,08 mil. USD	-151,58 mil. USD
2024e	536,46 mil. USD	28,12 mil. USD	-60,65 mil. USD
2025e	652,85 mil. USD	107,33 mil. USD	44,50 mil. USD
2026e	809,63 mil. USD	221,43 mil. USD	154,13 mil. USD
2027e	980,76 mil. USD	421,02 mil. USD	330,17 mil. USD
2028e	1,20 milijardi USD	574,12 mil. USD	547,09 mil. USD
2029e	1,39 milijardi USD	735,56 mil. USD	838,16 mil. USD
2030e	1,28 milijardi USD	829,46 mil. USD	670,53 mil. USD

2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023

4,30	24,40	54,70	161,50	121,10	78,20	107,40	55,70	99,10	82,00	151,70	214,00	330,40	358,60	504,20	452,70	483,30	482,50	293,60	286,20
0	0	0	0	0	0	0	5,00	3,20	1,10	0	0	1,30	9,50	22,00	33,30	46,90	52,70	66,20	87,63
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
0	0	0	0	0	0	0	0	0	0	0	0	3,40	4,60	8,40	14,00	19,60	26,80	23,80	59,70
0,20	0,40	0,30	1,50	2,50	2,30	2,20	5,90	2,30	5,20	2,90	2,60	5,00	19,30	16,60	20,00	29,70	34,80	40,20	49,53
4,50	24,80	55,00	163,00	123,60	80,50	109,60	66,60	104,60	88,30	154,60	216,60	340,10	392,00	551,20	520,00	579,50	596,80	423,80	483,06
0,50	3,30	4,40	3,80	4,90	4,40	2,60	2,40	5,00	4,10	2,80	6,20	9,80	9,10	11,40	81,00	67,20	63,10	60,30	57,98
0	0	0	0	0	0	0	0	0	0	17,50	0	0	0	0	0	0	0	0	0
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
0	0	0	0	0	0	0	0	0	23,00	23,00	486,70	486,70	23,00	23,00	23,00	23,00	23,00	23,00	20,49
0	0	0	0	0	0	0	0	0	11,60	11,60	197,80	197,80	197,80	197,80	197,80	197,80	197,80	197,80	197,80
0	0,50	0,30	0,30	0,30	0,50	0,30	0,70	0,40	0,60	0,50	1,10	2,50	5,20	6,70	28,30	19,10	24,40	19,20	18,55
0,50	3,80	4,70	4,10	5,20	4,90	2,90	3,10	5,40	39,30	55,40	691,80	696,80	235,10	238,90	330,10	307,10	308,30	300,30	294,82
0,01	0,03	0,06	0,17	0,13	0,09	0,11	0,07	0,11	0,13	0,21	0,91	1,04	0,63	0,79	0,85	0,89	0,91	0,72	0,78

20,00	60,50	124,20	0,30	0,30	0,30	0,40	0,40	0,60	0,70	1,00	1,30	1,50	1,70	1,90	2,60	2,70	2,80	2,80	2,92
0,00	0,00	0,01	0,23	0,23	0,24	0,29	0,30	0,39	0,42	0,57	0,92	1,12	1,40	1,74	2,23	2,31	2,60	2,66	2,84
-17,30	-37,30	-83,70	-124,80	-164,20	-170,80	-225,70	-270,10	-318,90	-378,50	-447,40	-570,80	-763,50	-1.047,50	-1.399,20	-1.756,20	-2.033,10	-2.295,80	-2.532,40	-2.684,00
-0,10	-2,50	0	0	0	0	0	0	0	0	0	0	1,90	-1,70	0,50	2,80	8,40	5,30	-12,00	5,43
0	0	0	400,00	500,00	0	0	0	0	0	-100,00	-100,00	100,00	-400,00	-400,00	0	-200,00	-300,00	-100,00	-188,00
4,20	24,70	46,60	103,30	71,00	71,80	64,90	29,60	69,20	45,80	122,20	347,90	360,20	352,90	342,90	476,40	286,40	307,40	123,00	160,17
0,60	0,90	1,20	0,50	2,00	3,80	2,00	2,60	2,10	2,10	5,90	16,50	12,90	16,40	44,40	51,40	17,10	21,50	15,40	15,12
0,20	1,40	7,70	9,90	6,80	5,80	6,30	7,10	6,70	8,00	10,50	15,70	27,80	37,20	36,20	68,90	88,40	95,20	88,70	129,76
0	0	0	3,80	3,70	0	6,60	8,50	0	0	0	41,40	70,00	16,20	5,50	8,60	24,20	29,30	34,90	22,81
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
0,20	0,30	1,30	1,50	0,90	1,60	1,30	1,00	0,40	0,30	3,80	0	0,30	0,30	0	0	0	0	0	0
1,00	2,60	10,20	15,70	13,40	11,20	16,20	19,20	9,20	10,40	20,20	73,60	111,00	70,10	86,10	128,90	129,70	146,00	139,00	167,69
0	0,70	2,30	1,20	0,30	2,30	1,00	0	0,30	14,20	10,50	0	154,50	164,20	321,70	149,50	389,30	389,40	392,00	387,86
0	0	0	0	0	0	0	0	0	9,20	9,20	176,20	173,80	6,50	6,50	5,10	4,90	4,90	4,90	0
0	0,70	0,60	46,80	44,00	0	30,40	20,90	31,30	48,00	47,90	310,70	237,50	33,50	32,70	90,40	76,30	57,50	65,20	62,16
0	1,40	2,90	48,00	44,30	2,30	31,40	20,90	31,60	71,40	67,60	486,90	565,80	204,20	360,90	245,00	470,50	451,80	462,10	450,02
1,00	4,00	13,10	63,70	57,70	13,50	47,60	40,10	40,80	81,80	87,80	560,50	676,80	274,30	447,00	373,90	600,20	597,80	601,10	617,71
0,01	0,03	0,06	0,17	0,13	0,09	0,11	0,07	0,11	0,13	0,21	0,91	1,04	0,63	0,79	0,85	0,89	0,91	0,72	0,78

Amicus Therapeutics Bruto marža	Amicus Therapeutics Profitna marža	Amicus Therapeutics EBIT marža	Amicus Therapeutics Profitna marža
2030e	90,65 %	64,55 %	52,18 %
2029e	90,65 %	52,96 %	60,34 %
2028e	90,65 %	47,80 %	45,55 %
2027e	90,65 %	42,93 %	33,67 %
2026e	90,65 %	27,35 %	19,04 %
2025e	90,65 %	16,44 %	6,82 %
2024e	90,65 %	5,24 %	-11,31 %
2023	90,65 %	-19,05 %	-37,96 %
2022	88,27 %	-62,42 %	-71,87 %
2021	88,71 %	-67,56 %	-82,00 %
2020	88,08 %	-94,67 %	-106,13 %
2019	87,98 %	-166,90 %	-195,61 %
2018	84,21 %	-360,53 %	-382,68 %
2017	83,20 %	63,41 %	-769,65 %
2016	82,00 %	-3.636,00 %	-4.000,00 %
2015	90,65 %	0 %	0 %
2014	90,65 %	-5.733,33 %	-5.741,67 %
2013	90,65 %	-15.425,00 %	-14.900,00 %
2012	90,65 %	-287,50 %	-265,22 %
2011	90,65 %	-237,85 %	-207,48 %
2010	90,65 %	-6.200,00 %	-6.100,00 %
2009	90,65 %	-9,16 %	-10,25 %
2008	90,65 %	-293,33 %	-262,67 %
2007	90,65 %	-2.544,44 %	-2.305,56 %
2006	90,65 %	0 %	0 %
2005	90,65 %	0 %	0 %
2004	90,65 %	0 %	0 %

	Bruto marža	EBIT marža	Profitna marža
2004	90,65 %	0 %	0 %
2005	90,65 %	0 %	0 %
2006	90,65 %	0 %	0 %
2007	90,65 %	-2.544,44 %	-2.305,56 %
2008	90,65 %	-293,33 %	-262,67 %
2009	90,65 %	-9,16 %	-10,25 %
2010	90,65 %	-6.200,00 %	-6.100,00 %
2011	90,65 %	-237,85 %	-207,48 %
2012	90,65 %	-287,50 %	-265,22 %
2013	90,65 %	-15.425,00 %	-14.900,00 %
2014	90,65 %	-5.733,33 %	-5.741,67 %
2015	90,65 %	0 %	0 %
2016	82,00 %	-3.636,00 %	-4.000,00 %
2017	83,20 %	63,41 %	-769,65 %
2018	84,21 %	-360,53 %	-382,68 %
2019	87,98 %	-166,90 %	-195,61 %
2020	88,08 %	-94,67 %	-106,13 %
2021	88,71 %	-67,56 %	-82,00 %
2022	88,27 %	-62,42 %	-71,87 %
2023	90,65 %	-19,05 %	-37,96 %
2024e	90,65 %	5,24 %	-11,31 %
2025e	90,65 %	16,44 %	6,82 %
2026e	90,65 %	27,35 %	19,04 %
2027e	90,65 %	42,93 %	33,67 %
2028e	90,65 %	47,80 %	45,55 %
2029e	90,65 %	52,96 %	60,34 %
2030e	90,65 %	64,55 %	52,18 %

Datum	Amicus Therapeutics Prihod po akciji	Amicus Therapeutics EBIT po akciji	Amicus Therapeutics Dobit po akciji
2030e	4,30 undefined	0 undefined	2,24 undefined
2029e	4,65 undefined	0 undefined	2,81 undefined
2028e	4,02 undefined	0 undefined	1,83 undefined
2027e	3,28 undefined	0 undefined	1,10 undefined
2026e	2,71 undefined	0 undefined	0,52 undefined
2025e	2,18 undefined	0 undefined	0,15 undefined
2024e	1,80 undefined	0 undefined	-0,20 undefined
2023	1,35 undefined	-0,26 undefined	-0,51 undefined
2022	1,14 undefined	-0,71 undefined	-0,82 undefined
2021	1,13 undefined	-0,76 undefined	-0,92 undefined
2020	1,01 undefined	-0,95 undefined	-1,07 undefined
2019	0,76 undefined	-1,26 undefined	-1,48 undefined
2018	0,49 undefined	-1,77 undefined	-1,88 undefined
2017	0,24 undefined	0,15 undefined	-1,85 undefined
2016	0,04 undefined	-1,35 undefined	-1,49 undefined
2015	0 undefined	-1,19 undefined	-1,20 undefined
2014	0,02 undefined	-0,92 undefined	-0,93 undefined
2013	0,01 undefined	-1,20 undefined	-1,16 undefined
2012	0,40 undefined	-1,16 undefined	-1,07 undefined
2011	0,62 undefined	-1,47 undefined	-1,28 undefined
2010	0,03 undefined	-2,01 undefined	-1,98 undefined
2009	2,85 undefined	-0,26 undefined	-0,29 undefined
2008	0,67 undefined	-1,96 undefined	-1,75 undefined
2007	0,14 undefined	-3,47 undefined	-3,14 undefined
2006	0 undefined	-2,11 undefined	-2,97 undefined
2005	0 undefined	-0,94 undefined	-0,91 undefined
2004	0 undefined	-0,38 undefined	-0,40 undefined

	Prihod po akciji	EBIT po akciji	Dobit po akciji
2004	0 USD	-0,38 USD	-0,40 USD
2005	0 USD	-0,94 USD	-0,91 USD
2006	0 USD	-2,11 USD	-2,97 USD
2007	0,14 USD	-3,47 USD	-3,14 USD
2008	0,67 USD	-1,96 USD	-1,75 USD
2009	2,85 USD	-0,26 USD	-0,29 USD
2010	0,03 USD	-2,01 USD	-1,98 USD
2011	0,62 USD	-1,47 USD	-1,28 USD
2012	0,40 USD	-1,16 USD	-1,07 USD
2013	0,01 USD	-1,20 USD	-1,16 USD
2014	0,02 USD	-0,92 USD	-0,93 USD
2015	0 USD	-1,19 USD	-1,20 USD
2016	0,04 USD	-1,35 USD	-1,49 USD
2017	0,24 USD	0,15 USD	-1,85 USD
2018	0,49 USD	-1,77 USD	-1,88 USD
2019	0,76 USD	-1,26 USD	-1,48 USD
2020	1,01 USD	-0,95 USD	-1,07 USD
2021	1,13 USD	-0,76 USD	-0,92 USD
2022	1,14 USD	-0,71 USD	-0,82 USD
2023	1,35 USD	-0,26 USD	-0,51 USD
2024e	1,80 USD	0 USD	-0,20 USD
2025e	2,18 USD	0 USD	0,15 USD
2026e	2,71 USD	0 USD	0,52 USD
2027e	3,28 USD	0 USD	1,10 USD
2028e	4,02 USD	0 USD	1,83 USD
2029e	4,65 USD	0 USD	2,81 USD
2030e	4,30 USD	0 USD	2,24 USD

Datum	Ex-U.S	U.S
2023	252,42 mil. USD	146,94 mil. USD
2022	213,29 mil. USD	115,95 mil. USD
2021	210,13 mil. USD	95,39 mil. USD
2019	129,76 mil. USD	52,48 mil. USD

	Ex-U.S	U.S
2019	129,76 mil. USD	52,48 mil. USD
2021	210,13 mil. USD	95,39 mil. USD
2022	213,29 mil. USD	115,95 mil. USD
2023	252,42 mil. USD	146,94 mil. USD

	Broj akcija
2004	22,20 mil. Aktien
2005	22,20 mil. Aktien
2006	22,20 mil. Aktien
2007	13,20 mil. Aktien
2008	22,50 mil. Aktien
2009	22,60 mil. Aktien
2010	27,70 mil. Aktien
2011	34,60 mil. Aktien
2012	45,60 mil. Aktien
2013	51,30 mil. Aktien
2014	74,40 mil. Aktien
2015	109,90 mil. Aktien
2016	134,40 mil. Aktien
2017	153,40 mil. Aktien
2018	185,80 mil. Aktien
2019	240,40 mil. Aktien
2020	258,90 mil. Aktien
2021	271,40 mil. Aktien
2022	289,10 mil. Aktien
2023	295,16 mil. Aktien
2024e	295,16 mil. Aktien
2025e	295,16 mil. Aktien
2026e	295,16 mil. Aktien
2027e	295,16 mil. Aktien
2028e	295,16 mil. Aktien
2029e	295,16 mil. Aktien
2030e	295,16 mil. Aktien

Datum	Procena EPSa	EPS-Actual	Kvartal izveštaja
30. 9. 2024.	0	-0,02 (0 %)	2024 Q3
30. 6. 2024.	-0,06	-0,05 (11,66 %)	2024 Q2
31. 3. 2024.	-0,07	-0,16 (-139,16 %)	2024 Q1
31. 12. 2023.	-0,06	-0,11 (-83,03 %)	2023 Q4
30. 9. 2023.	-0,08	-0,07 (9,21 %)	2023 Q3
30. 6. 2023.	-0,13	-0,15 (-19,24 %)	2023 Q2
31. 3. 2023.	-0,15	-0,18 (-20,32 %)	2023 Q1
31. 12. 2022.	-0,13	-0,19 (-47,40 %)	2022 Q4
30. 9. 2022.	-0,19	-0,12 (36,88 %)	2022 Q3
30. 6. 2022.	-0,22	-0,21 (5,11 %)	2022 Q2
31. 3. 2022.	-0,26	-0,30 (-15,34 %)	2022 Q1
31. 12. 2021.	-0,16	-0,29 (-82,28 %)	2021 Q4
30. 9. 2021.	-0,17	-0,19 (-10,79 %)	2021 Q3
30. 6. 2021.	-0,22	-0,19 (11,87 %)	2021 Q2
31. 3. 2021.	-0,24	-0,25 (-4,30 %)	2021 Q1
31. 12. 2020.	-0,22	-0,27 (-21,90 %)	2020 Q4
30. 9. 2020.	-0,22	-0,23 (-2,91 %)	2020 Q3
30. 6. 2020.	-0,27	-0,20 (24,67 %)	2020 Q2
31. 3. 2020.	-0,29	-0,34 (-17,65 %)	2020 Q1
31. 12. 2019.	-0,28	-0,35 (-25,67 %)	2019 Q4
30. 9. 2019.	-0,33	-0,24 (26,45 %)	2019 Q3
30. 6. 2019.	-0,33	-0,36 (-8,40 %)	2019 Q2
31. 3. 2019.	-0,31	-0,39 (-23,85 %)	2019 Q1
31. 12. 2018.	-0,28	-0,41 (-44,01 %)	2018 Q4
30. 9. 2018.	-0,28	-0,31 (-9,93 %)	2018 Q3
30. 6. 2018.	-0,33	-0,33 (0,96 %)	2018 Q2
31. 3. 2018.	-0,37	-0,28 (24,45 %)	2018 Q1
31. 12. 2017.	-0,30	-0,41 (-35,49 %)	2017 Q4
30. 9. 2017.	-0,32	-0,41 (-29,66 %)	2017 Q3
30. 6. 2017.	-0,37	-0,34 (6,98 %)	2017 Q2
31. 3. 2017.	-0,37	-0,39 (-6,79 %)	2017 Q1
31. 12. 2016.	-0,34	-0,42 (-24,30 %)	2016 Q4
30. 9. 2016.	-0,32	-0,33 (-2,71 %)	2016 Q3
30. 6. 2016.	-0,34	-0,40 (-18,84 %)	2016 Q2
31. 3. 2016.	-0,35	-0,35 (-1,42 %)	2016 Q1
31. 12. 2015.	-0,31	-0,36 (-15,72 %)	2015 Q4
30. 9. 2015.	-0,25	-0,32 (-27,54 %)	2015 Q3
30. 6. 2015.	-0,25	-0,26 (-5,09 %)	2015 Q2
31. 3. 2015.	-0,21	-0,25 (-19,56 %)	2015 Q1
31. 12. 2014.	-0,18	-0,24 (-30,72 %)	2014 Q4
30. 9. 2014.	-0,21	-0,22 (-2,71 %)	2014 Q3
30. 6. 2014.	-0,24	-0,22 (7,25 %)	2014 Q2
31. 3. 2014.	-0,25	-0,25 (-1,05 %)	2014 Q1
31. 12. 2013.	-0,33	-0,18 (45,19 %)	2013 Q4
30. 9. 2013.	-0,35	-0,29 (16,79 %)	2013 Q3
30. 6. 2013.	-0,35	-0,31 (12,08 %)	2013 Q2
31. 3. 2013.	-0,33	-0,35 (-5,36 %)	2013 Q1
31. 12. 2012.	-0,38	-0,20 (47,62 %)	2012 Q4
30. 9. 2012.	-0,24	-0,34 (-38,89 %)	2012 Q3
30. 6. 2012.	-0,24	-0,20 (15,29 %)	2012 Q2
31. 3. 2012.	-0,36	-0,35 (3,34 %)	2012 Q1
31. 12. 2011.	-0,38	-0,25 (34,35 %)	2011 Q4
30. 9. 2011.	-0,34	-0,28 (17,65 %)	2011 Q3
30. 6. 2011.	-0,32	-0,37 (-14,80 %)	2011 Q2
31. 3. 2011.	-0,36	-0,39 (-9,24 %)	2011 Q1
31. 12. 2010.	-0,16	-0,48 (-209,68 %)	2010 Q4
30. 9. 2010.	-0,50	-0,56 (-11,47 %)	2010 Q3
30. 6. 2010.	-0,54	-0,41 (24,16 %)	2010 Q2
31. 3. 2010.	-0,59	-0,54 (8,72 %)	2010 Q1
31. 12. 2009.	-0,60	1,52 (352,58 %)	2009 Q4
30. 9. 2009.	-0,70	-0,59 (15,56 %)	2009 Q3
30. 6. 2009.	-0,67	-0,60 (10,19 %)	2009 Q2
31. 3. 2009.	-0,65	-0,55 (15,75 %)	2009 Q1
31. 12. 2008.	-0,63	-0,63 (0,38 %)	2008 Q4
30. 9. 2008.	-0,48	-0,36 (24,91 %)	2008 Q3
30. 6. 2008.	-0,53	-0,41 (21,95 %)	2008 Q2
31. 3. 2008.	-0,39	-0,34 (11,71 %)	2008 Q1
31. 12. 2007.	-0,41	-0,53 (-29,90 %)	2007 Q4
30. 9. 2007.	-0,47	-0,46 (1,96 %)	2007 Q3
30. 6. 2007.	-0,49	-1,37 (-178,34 %)	2007 Q2

%	Ime	Акције	Promena	Datum
9,55329 %	The Vanguard Group, Inc.	28.546.190	384.297	30. 6. 2024.
9,38973 %	Perceptive Advisors LLC	28.057.456	0	30. 6. 2024.
9,16971 %	Avoro Capital Advisors LLC	27.400.000	0	30. 6. 2024.
7,17328 %	BlackRock Institutional Trust Company, N.A.	21.434.490	1.019.701	30. 6. 2024.
7,06400 %	Wellington Management Company, LLP	21.107.943	2.304.298	30. 6. 2024.
4,42803 %	Janus Henderson Investors	13.231.394	-583.120	30. 6. 2024.
4,35172 %	William Blair Investment Management, LLC	13.003.363	1.477.084	30. 6. 2024.
3,68695 %	State Street Global Advisors (US)	11.016.963	-1.425.538	30. 6. 2024.
3,64629 %	JP Morgan Asset Management	10.895.485	-311.708	30. 6. 2024.
3,54576 %	Redmile Group, LLC	10.595.089	-2.662.197	30. 6. 2024.
3,02193 %	Palo Alto Investors LP	9.029.843	-314.259	30. 6. 2024.
2,38319 %	Macquarie Investment Management	7.121.222	50.489	30. 6. 2024.
2,18164 %	Geode Capital Management, L.L.C.	6.518.945	308.209	30. 6. 2024.
1,74115 %	Fiera Capital Inc.	5.202.718	36.807	30. 6. 2024.
1,51853 %	Morgan Stanley & Co. LLC	4.537.524	-4.377.590	30. 6. 2024.
1,41100 %	Pictet Asset Management Ltd.	4.216.211	-2.551.162	30. 6. 2024.
1,31303 %	American Century Investment Management, Inc.	3.923.465	-877.434	30. 6. 2024.
1,20489 %	JPMorgan Asset Management U.K. Limited	3.600.334	-479.256	30. 6. 2024.
1,01086 %	MFS Investment Management	3.020.536	378.999	30. 6. 2024.
1,00964 %	Citadel Advisors LLC	3.016.896	1.665.714	30. 6. 2024.
0,97876 %	Norges Bank Investment Management (NBIM)	2.924.645	393.645	30. 6. 2024.
0,87772 %	DWS Investments UK Limited	2.622.723	-1.384.742	30. 6. 2024.
0,84020 %	Invesco Advisers, Inc.	2.510.592	2.269.255	30. 6. 2024.
0,83665 %	Novo Holdings A/S	2.500.000	0	30. 9. 2024.
0,81142 %	Charles Schwab Investment Management, Inc.	2.424.599	97.672	30. 6. 2024.
0,78861 %	Northern Trust Investments, Inc.	2.356.437	-104.961	30. 6. 2024.
0,76100 %	Victory Capital Management Inc.	2.273.959	345.117	30. 6. 2024.
0,68200 %	Assenagon Asset Management S.A.	2.037.896	1.192.489	30. 9. 2024.
0,63391 %	Millennium Management LLC	1.894.176	1.792.277	30. 6. 2024.
0,63141 %	Nuveen LLC	1.886.725	748.625	30. 6. 2024.
0,59626 %	Pictet Asset Management (Japan) Ltd.	1.781.682	88.689	30. 4. 2024.
0,59601 %	abrdn Inc.	1.780.934	145.227	30. 9. 2024.
0,52856 %	BlackRock Financial Management, Inc.	1.579.378	448.832	30. 6. 2024.
0,50049 %	Great Point Partners, LLC	1.495.500	0	30. 6. 2024.
0,50033 %	StemPoint Capital LP	1.495.047	-52.094	30. 6. 2024.
0,47887 %	PanAgora Asset Management Inc.	1.430.923	-98.239	30. 6. 2024.
0,43380 %	Voloridge Investment Management, LLC	1.296.235	-16.935	30. 6. 2024.
0,43096 %	Voya Investment Management LLC	1.287.754	255.038	30. 6. 2024.
0,41282 %	Blackstone Alternative Credit Advisors LP	1.233.552	0	30. 6. 2024.
0,41282 %	Clarus Ventures, LLC	1.233.552	0	30. 6. 2024.
0,40781 %	Rock Springs Capital Management LP	1.218.580	65.924	30. 6. 2024.
0,40676 %	T. Rowe Price Associates, Inc.	1.215.425	-13.234	30. 6. 2024.
0,37385 %	Balyasny Asset Management LP	1.117.100	1.117.100	30. 6. 2024.
0,37220 %	Managed Account Advisors LLC	1.112.171	-61.372	30. 6. 2024.
0,35725 %	Hudson Bay Capital Management LP	1.067.500	265.000	30. 6. 2024.
0,35333 %	Goldman Sachs & Company, Inc.	1.055.790	52.152	30. 6. 2024.
0,35223 %	PRIMECAP Management Company	1.052.500	-41.700	30. 6. 2024.
0,34748 %	Fidelity Management & Research Company LLC	1.038.307	-709.239	30. 6. 2024.
0,32534 %	Rice Hall James & Associates, LLC	972.138	-146	30. 9. 2024.
0,30706 %	New York State Common Retirement Fund	917.514	-633.662	30. 9. 2024.
0,29969 %	BofA Global Research (US)	895.516	147.304	30. 6. 2024.
0,27482 %	Granite Investment Partners, LLC	821.178	-97.656	30. 6. 2024.
0,26154 %	ExodusPoint Capital Management, LP	781.517	138.132	30. 6. 2024.
0,26061 %	BlackRock Investment Management, LLC	778.728	51.887	30. 6. 2024.
0,25495 %	Neuberger Berman, LLC	761.810	293.158	30. 6. 2024.
0,25048 %	M&G Investment Management Ltd.	748.451	82.728	30. 6. 2024.
0,24926 %	Peregrine Capital Management, LLC	744.801	-68.137	30. 9. 2024.
0,23943 %	BNY Mellon Asset Management	715.448	44.286	30. 6. 2024.
0,23879 %	Saturn V Capital Management LP	713.536	-184.845	30. 6. 2024.
0,23072 %	Osterweis Capital Management, LLC	689.425	205.365	30. 6. 2024.
0,21772 %	Squarepoint Capital LLP	650.555	399.449	30. 6. 2024.
0,21159 %	Jane Street Capital, L.L.C.	632.266	484.899	30. 6. 2024.
0,21151 %	Renaissance Technologies LLC	632.024	-324.176	30. 6. 2024.
0,20745 %	Northern Trust Global Investments	619.888	-2.781	30. 6. 2024.
0,19086 %	OrbiMed Advisors, LLC	570.300	0	30. 6. 2024.
0,18096 %	Silvercrest Asset Management Group LLC	540.738	165.780	30. 6. 2024.
0,17293 %	Wells Fargo Advisors	516.740	-6.912	30. 6. 2024.
0,17068 %	Schroder Investment Management Ltd. (SIM)	510.000	0	30. 6. 2024.
0,16815 %	Parkman Healthcare Partners LLC	502.463	275.740	30. 6. 2024.
0,16354 %	Mellon Investments Corporation	488.669	73.739	30. 6. 2024.
0,16290 %	UBS Financial Services, Inc.	486.767	-411.129	30. 6. 2024.
0,15781 %	Campbell (Bradley Lewis)	471.552	0	1. 10. 2024.
0,15283 %	Rafferty Asset Management LLC	456.669	-288.905	30. 6. 2024.
0,15087 %	Envestnet Asset Management, Inc.	450.823	16.263	30. 6. 2024.
0,15060 %	CM Management, LLC	450.000	0	30. 6. 2024.
0,14545 %	Rhumbline Advisers Ltd. Partnership	434.612	19.491	30. 6. 2024.
0,14534 %	Schweizerische Nationalbank	434.300	0	30. 6. 2024.
0,13753 %	Goldman Sachs Asset Management, L.P.	410.950	105.455	30. 6. 2024.
0,13525 %	Medical Strategy GmbH	404.130	-38.612	30. 6. 2024.
0,13345 %	Barclays Bank PLC	398.767	106.792	30. 6. 2024.
0,12743 %	Columbia Threadneedle Investments (US)	380.787	8.391	30. 6. 2024.
0,12437 %	Conestoga Capital Advisors, LLC	371.627	-3.575	31. 3. 2024.
0,12048 %	DWS Investment GmbH	360.000	30.000	30. 6. 2024.
0,11770 %	BlackRock Advisors (UK) Limited	351.695	5.245	30. 9. 2024.
0,11708 %	State of Wisconsin Investment Board	349.843	43.229	30. 6. 2024.
0,11520 %	AllianceBernstein L.P.	344.229	21.870	30. 6. 2024.
0,11404 %	BNP Paribas Securities Corp. North America	340.754	-247.881	30. 6. 2024.
0,11233 %	JPMorgan Private Bank (United States)	335.652	-273	30. 6. 2024.
0,10939 %	Transcend Capital Advisors, LLC	326.854	-3.473	30. 9. 2024.
0,10155 %	Susquehanna International Group, LLP	303.448	201.825	30. 6. 2024.
0,10143 %	PGIM Quantitative Solutions LLC	303.069	223.035	30. 6. 2024.
0,10032 %	BlackRock Asset Management Ireland Limited	299.758	7.785	30. 6. 2024.
0,09426 %	Ambassador Advisors, LLC	281.659	8.151	30. 6. 2024.
0,09354 %	Quimi (Daphne)	279.509	29.518	12. 4. 2024.
0,09096 %	Hillsdale Investment Management Inc.	271.800	-48.000	30. 6. 2024.
0,08994 %	Essex Investment Management Company, LLC	268.743	743	30. 9. 2024.
0,08839 %	Allianz Global Investors GmbH	264.111	0	30. 6. 2024.
0,08506 %	RBC Capital Markets Wealth Management	254.156	11.020	30. 6. 2024.
0,08382 %	UBS Fund Management (Switzerland) AG	250.464	-72.080	30. 6. 2024.
0,08376 %	Mutual of America Capital Management LLC	250.293	48.802	30. 6. 2024.

What values and corporate philosophy does Amicus Therapeutics represent?

Amicus Therapeutics Inc represents values of innovation, dedication, and patient-centricity. With a corporate philosophy focused on delivering life-changing therapies, Amicus strives to improve the lives of individuals with rare and devastating diseases. The company is committed to advancing science, developing transformative medicines, and ensuring access to those therapies for patients in need. Amicus fosters a collaborative and compassionate approach, working closely with patient advocacy groups, healthcare professionals, and regulatory authorities to make a meaningful impact in the lives of the communities it serves.

In which countries and regions is Amicus Therapeutics primarily present?

Amicus Therapeutics Inc is primarily present in the United States.

What significant milestones has the company Amicus Therapeutics achieved?

Amicus Therapeutics Inc has achieved significant milestones in its journey. Some notable accomplishments include the approval of Galafold, a breakthrough therapy for Fabry disease, by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). Additionally, the company has made remarkable progress in developing innovative therapies for rare genetic diseases such as Pompe disease and other lysosomal storage disorders. Amicus Therapeutics Inc has successfully conducted clinical trials and obtained positive results, showcasing their commitment to advancing medical science and improving patients' lives. Their unwavering dedication has positioned them as a leading player in the biopharmaceutical industry.

What is the history and background of the company Amicus Therapeutics?

Amicus Therapeutics Inc is a biopharmaceutical company headquartered in Cranbury, New Jersey. Founded in 2002, Amicus Therapeutics focuses on developing advanced therapies for rare and orphan diseases. The company's innovative approach is based on the principles of personalized medicine, utilizing breakthrough science and technology. Over the years, Amicus Therapeutics has established itself as a leader in the field, with a strong dedication to improving the lives of patients with devastating genetic diseases. Through its robust research and development efforts, Amicus Therapeutics has successfully advanced several potential treatments, striving to bring hope and transformative therapies to those in need.

Who are the main competitors of Amicus Therapeutics in the market?

The main competitors of Amicus Therapeutics Inc in the market include companies such as Vertex Pharmaceuticals, BioMarin Pharmaceutical, and Sanofi Genzyme.

In which industries is Amicus Therapeutics primarily active?

Amicus Therapeutics Inc is primarily active in the biotechnology industry.

What is the business model of Amicus Therapeutics?

The business model of Amicus Therapeutics Inc. revolves around developing advanced therapies for rare and orphan diseases. The company focuses on utilizing its Chaperone-Advanced Replacement Therapy (CHART™) platform to deliver enzyme replacement therapies (ERTs) for individuals suffering from lysosomal storage disorders (LSDs). As a biopharmaceutical company, Amicus Therapeutics aims to address unmet medical needs through innovative drug research and development. By leveraging their expertise in protein misfolding and folding, Amicus Therapeutics aims to improve the lives of patients with genetic diseases.

Koji P/E odnos ima Amicus Therapeutics 2024?

P/E odnos Amicus Therapeutics iznosi -48,81.

Koji je KUV za Amicus Therapeutics 2024?

KUV kompanije Amicus Therapeutics iznosi 5,52.

Koji AlleAktien kvalitetni skor ima Amicus Therapeutics?

AlleAktien kvalitativni skor za Amicus Therapeutics je 4/10.

Koliki je prihod od Amicus Therapeutics 2024?

očekivana Amicus Therapeutics promet je 536,46 mil. USD.

Koliki je profit kompanije Amicus Therapeutics 2024?

Dobit očekivana Amicus Therapeutics je -60,65 mil. USD.

Шта ради Amicus Therapeutics?

Amicus Therapeutics Inc (Nasdaq: FOLD) aims to develop and manufacture novel therapies for people with rare and severe diseases. The biotechnology company, based in Cranbury, New Jersey, USA, focuses on researching and developing drugs that aim to influence the natural metabolism of proteins in the body to treat diseases caused by mutations in genes. The business model of Amicus Therapeutics is based on the discovery and development of therapies specialized in treating rare and severe diseases. The company works closely with patients and their families to gain a better understanding of the needs and challenges of these patient groups. Amicus utilizes a proprietary technology platform called Chaperon-Advanced Replacement Therapy (CHART), which allows for the treatment of Ectopic Glycosylation Disorders (EGS) by replacing faulty proteins produced by gene mutations with functional and stable therapeutics. Amicus Therapeutics specializes in the following three areas: 1. Fabry disease: A rare lysosomal metabolic disorder where the Alpha-Galactosidase-A enzyme is not produced normally due to mutations in the GLA gene. Amicus has developed Galafold, the first oral medication for treating Fabry disease, which aims to stabilize the faulty protein. 2. Pompe disease: A lysosomal storage disease characterized by a deficiency of enzymes that help in breaking down glycogen. This results in an accumulation of glycogen in various tissues and organs. Amicus has developed ATB200/AT2221, a combined therapy of enzyme replacement therapy and chaperone therapy aimed at correcting the enzyme deficiency caused by mutation. 3. Phenylketonuria (PKU): A metabolic disorder where an individual lacks the ability to metabolize phenylalanine. This leads to an accumulation of phenylalanine in the body, which can cause impairments to the central nervous system. Amicus has a pipeline of therapeutics in development for treating PKU, including a chaperone platform and an enzyme replacement therapy. Amicus Therapeutics collaborates closely with medical centers, patient organizations, and research institutions to develop innovative therapies for rare and severe diseases. The company is committed to enhancing the effectiveness and safety of medications, helping to improve the quality of life for affected individuals. By focusing on rare and severe diseases, Amicus Therapeutics can serve a niche and position itself as an innovator in the biotechnology industry. Overall, Amicus Therapeutics' business model has the potential to achieve significant medical advancements while also being profitable. The company is well-positioned to continue developing innovative therapies for rare and severe diseases that can improve the lives of patients and their families.

Kolika je Amicus Therapeutics dividenda?

Amicus Therapeutics isplaćuje dividendu od 0 USD raspoređenu preko isplata u toku godine.

Koliko često Amicus Therapeutics isplaćuje dividendu?

Dividenda za Amicus Therapeutics trenutno ne može biti izračunata ili kompanija ne isplaćuje dividendu.

Šta je Amicus Therapeutics ISIN?

ISIN od Amicus Therapeutics je US03152W1099.

Šta je Amicus Therapeutics WKN?

WKN od Amicus Therapeutics je A0MSMZ.

Koji je Amicus Therapeutics berzanski simbol?

Oznaka za praćenje akcija kompanije Amicus Therapeutics je FOLD.

Kolika je dividenda koju isplaćuje Amicus Therapeutics?

U poslednjih 12 meseci, Amicus Therapeutics je isplatio dividendu u iznosu od . To odgovara dividendnom prinosu od oko . Za narednih 12 meseci, Amicus Therapeutics će verovatno isplatiti dividendu od 0 USD.

Kolika je dividendna prinosa za Amicus Therapeutics?

Dividendski prinos od Amicus Therapeutics trenutno iznosi .

Kada Amicus Therapeutics isplaćuje dividendu?

Amicus Therapeutics isplaćuje dividende na kvartalnom nivou. One se isplaćuju u mesecima .

Koliko je sigurna dividenda od Amicus Therapeutics?

Amicus Therapeutics je isplaćivao dividendu svake godine u poslednjih 0 godina.

Kolika je dividenda kompanije Amicus Therapeutics?

Za narednih 12 meseci očekuju se dividende u iznosu od 0 USD. To odgovara dividendnom prinosu od 0 %.

U kom sektoru se nalazi Amicus Therapeutics?

Amicus Therapeutics se svrstava u sektor 'Zdravlje'.

Wann musste ich die Aktien von Amicus Therapeutics kaufen, um die vorherige Dividende zu erhalten?

Da biste primili poslednju dividendu od Amicus Therapeutics od 21. 12. 2024. u iznosu od 0 USD, morali ste da imate akciju u depou pre Ex-dana 21. 12. 2024..

Kada je Amicus Therapeutics poslednji put isplatio dividendu?

Isplata poslednje dividende izvršena je 21. 12. 2024..

Kolika je bila dividenda od Amicus Therapeutics u godini 2023?

U godini 2023 kompanija Amicus Therapeutics je isplatila 0 USD kao dividende.

U kojoj valuti Amicus Therapeutics isplaćuje dividendu?

Dividende od Amicus Therapeutics se isplaćuju u USD.

2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024e	2025e	2026e	2027e	2028e	2029e	2030e
0	0	0	0	0,00	0,02	0,06	0	0,02	0,02	0	0,00	0	0,01	0,04	0,09	0,18	0,26	0,31	0,33	0,40	0,54	0,65	0,81	0,98	1,20	1,39	1,28
-	-	-	-	-	1.400,00	326,67	-	-	-14,29	-	-	-	-	620,00	152,78	100,00	42,86	17,31	7,87	21,28	34,34	21,64	24,08	21,14	22,45	15,67	-7,49
-	-	-	-	36.200,00	2.413,33	565,63	-	1.723,81	2.011,11	-	36.200,00	-	80,00	83,33	83,52	87,91	88,08	88,85	88,15	90,73	67,54	55,52	44,75	36,94	30,17	26,08	28,19
0	0	0	0	0	0	0	0	0	0	0	0	0	4,00	30,00	76,00	160,00	229,00	271,00	290,00	362,00	0	0	0	0	0	0	0
-6,00	-8,00	-20,00	-65,00	-41,00	-39,00	-6,00	-54,00	-44,00	-48,00	-59,00	-68,00	-132,00	-200,00	-284,00	-349,00	-356,00	-276,00	-250,00	-236,00	-151,00	-60,00	44,00	154,00	330,00	547,00	838,00	670,00
-	33,33	150,00	225,00	-36,92	-4,88	-84,62	800,00	-18,52	9,09	22,92	15,25	94,12	51,52	42,00	22,89	2,01	-22,47	-9,42	-5,60	-36,02	-60,26	-173,33	250,00	114,29	65,76	53,20	-20,05
22,20	22,20	22,20	22,20	13,20	22,50	22,60	27,70	34,60	45,60	51,30	74,40	109,90	134,40	153,40	185,80	240,40	258,90	271,40	289,10	295,16	0	0	0	0	0	0	0
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023
-6,00	-8,00	-19,00	-46,00	-41,00	-39,00	-6,00	-54,00	-44,00	-48,00	-59,00	-68,00	-132,00	-200,00	-284,00	-349,00	-356,00	-276,00	-250,00	-236,00	-151,00
0	0	0	0	1,00	1,00	2,00	2,00	1,00	1,00	1,00	1,00	1,00	3,00	3,00	4,00	4,00	8,00	6,00	5,00	7,00
0	0	0	0	0	0	0	0	0	0	0	0	0	-3,00	-167,00	0	-1,00	0	0	0	-4,00
1,00	-1,00	0	6,00	50,00	-5,00	-46,00	31,00	-12,00	7,00	4,00	9,00	14,00	1,00	-24,00	-4,00	11,00	-32,00	-28,00	-39,00	-47,00
1,00	0	0	4,00	4,00	12,00	15,00	13,00	14,00	11,00	13,00	12,00	25,00	66,00	281,00	78,00	135,00	116,00	128,00	181,00	213,00
0	0	0	0	0	0	0	0	0	0	0	1,00	0	2,00	7,00	7,00	16,00	24,00	30,00	34,00	36,00
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	10,00	20,00	1,00	8,00
-3,00	-9,00	-18,00	-33,00	15,00	-36,00	-43,00	-13,00	-49,00	-33,00	-45,00	-51,00	-100,00	-150,00	-213,00	-299,00	-250,00	-233,00	-202,00	-166,00	-69,00
-1,00	0	-3,00	-2,00	0	-2,00	-1,00	0	-1,00	-4,00	0	0	-4,00	-5,00	-4,00	-6,00	-20,00	-3,00	-3,00	-3,00	-7,00
-1,00	-4,00	-16,00	-26,00	-75,00	21,00	31,00	-19,00	46,00	-39,00	26,00	-107,00	-145,00	-4,00	-171,00	-121,00	95,00	-13,00	78,00	92,00	98,00
0	-4,00	-13,00	-24,00	-74,00	24,00	33,00	-19,00	47,00	-35,00	26,00	-106,00	-140,00	1,00	-166,00	-114,00	115,00	-10,00	82,00	96,00	105,00
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
3,00	1,00	0	0	-1,00	-1,00	2,00	-1,00	-1,00	0	14,00	0	34,00	192,00	0	146,00	0	230,00	0	0	-20,00
0	12,00	40,00	63,00	92,00	0	0	45,00	0	81,00	15,00	139,00	258,00	100,00	259,00	307,00	201,00	42,00	229,00	4,00	103,00
3,00	13,00	41,00	66,00	91,00	-1,00	2,00	43,00	0	81,00	29,00	139,00	290,00	272,00	247,00	450,00	217,00	262,00	212,00	-7,00	61,00
0	0	1,00	3,00	0	0	0	0	0	0	0	0	-2,00	-19,00	-11,00	-2,00	16,00	-10,00	-16,00	-11,00	-20,00
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
-1,00	0	6,00	5,00	32,00	-16,00	-8,00	10,00	-3,00	8,00	9,00	-19,00	45,00	117,00	-136,00	31,00	63,00	19,00	83,00	-96,00	96,00
-4,97	-9,46	-21,16	-35,92	14,52	-39,53	-45,18	-14,36	-50,84	-38,06	-46,49	-51,91	-104,96	-156,10	-218,23	-306,27	-270,43	-236,52	-206,37	-170,35	-76,53
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0

Direktne emisije
Indirektne emisije iz kupljene energije
Indirektne emisije unutar lanca vrednosti
CO₂ emisije
Strategija redukcije CO₂
Ugalj energija
Atomska energija
Eksperimenti na životinjama
Pelz & Leder
Pesticidi
Palmino ulje
Tabak
Gentechnika
Koncept klime
Održivo šumarstvo
Pravila o reciklaži
Ekološka ambalaža
Opasne materije
Potrošnja i efikasnost goriva
Potrošnja i efikasnost vode

Udeo žena zaposlenih	57
Udeo žena u menadžmentu
Udeo azijskih zaposlenih
Udeo azijskog menadžmenta
Udeo hispansko/latinskih zaposlenih
Udeo hispano/latino menadžmenta
Udeo crnačkih zaposlenih
Udeo crnačkog menadžmenta
Udeo belih zaposlenih
Udeo belačkog menadžmenta
Sadržaji za odrasle
Alkohol
Odbrana
oružje
Kockanje
Ugovori o vojsci
Koncept ljudskih prava
Koncept zaštite podataka
Zaštita na radu i zdravlje
Katolički

Izveštaj o održivosti
Angažovanje zainteresovanih strana
Politika povlačenja
Antimonopolsko pravo

Berza	Amicus Therapeutics Тикер
DIZELDORF	AM6.DU
FRANKFURT	AM6.F
LONDON	0HF9.L
LONDON STOCK EXCHANGE	0HF9.L
MINHEN	AM6.MU
NASDAQ	FOLD

Amicus Therapeutics Тикер	Amicus Therapeutics FIGI
AM6:GR	BBG000F0TV39
AM6:GF	BBG000F0TVG5
AM6:GD	BBG000F0TVT1
AM6:GS	BBG000F0VYF7
AM6:GM	BBG000F0VZ55
AM6:GB	BBG000F0VZK8
FOLD:US	BBG000PLF6N0
FOLD:UA	BBG000PLF7J3
FOLD:UC	BBG000PLF7M9
FOLD:UN	BBG000PLF810
FOLD:UP	BBG000PLF8J1
FOLD:UQ	BBG000PLF8M7
FOLD:UB	BBG000PLF9T8
FOLD:UM	BBG000PLFBV0
FOLD:UX	BBG000PLFC48
FOLD:UD	BBG000PLFGG6
FOLD:UF	BBG000PLFHJ1
FOLD:VY	BBG000PLFHQ3
FOLD:VJ	BBG000PLFHT0
FOLD:VK	BBG000PLFJ43
FOLD:VF	BBG00DJGGGP5
AM6:TH	BBG00H45FFR7
FOLDEUR:EO	BBG00H4G0DD9
FOLDEUR:XH	BBG00H4G0DH5
FOLDEUR:XF	BBG00H4G0DK1
FOLDEUR:XE	BBG00H4G0DM9
FOLDEUR:XJ	BBG00H4G0DN8
FOLDEUR:XL	BBG00H4G0DP6
FOLDEUR:XG	BBG00H4G0DQ5
FOLDEUR:XO	BBG00H4G0DR4
FOLDEUR:XS	BBG00H4G0DW8
FOLDEUR:XA	BBG00H4G0DX7
FOLDEUR:E1	BBG00H4G0DY6
FOLDEUR:XT	BBG00H4G0DZ5
FOLDEUR:XW	BBG00H4G0F08
FOLDEUR:XU	BBG00H4G0F17
FOLDEUR:XV	BBG00H4G0F26
FOLDEUR:EU	BBG00H4G0F44
AM6:QT	BBG00H50QP84
FOLDEUR:XX	BBG00JN8MYF0
FOLDUSD:X2	BBG00JQBM439
FOLDUSD:XB	BBG00JQBM448
FOLDUSD:XH	BBG00JQBM466
FOLDUSD:XF	BBG00JQBM484
FOLDUSD:XE	BBG00JQBM4B0
FOLDUSD:XJ	BBG00JQBM4C9
FOLDUSD:XL	BBG00JQBM4D8
FOLDUSD:XG	BBG00JQBM4F6
FOLDUSD:XO	BBG00JQBM4G5
FOLDUSD:XS	BBG00JQBM4L9
FOLDUSD:XA	BBG00JQBM4M8
FOLDUSD:E1	BBG00JQBM4N7
FOLDUSD:XT	BBG00JQBM4P5
FOLDUSD:XW	BBG00JQBM4Q4
FOLDUSD:XU	BBG00JQBM4R3
FOLDUSD:XV	BBG00JQBM4S2
FOLDUSD:XM	BBG00JQBM4T1
FOLDUSD:XQ	BBG00JQBM4W7
FOLDUSD:XX	BBG00JQBM4X6
FOLDUSD:XZ	BBG00JQBM4Y5
FOLDUSD:EU	BBG00JQBM509
0HF9:LN	BBG00JVRN5G0
FOLDGBX:X2	BBG00K2PDF36
FOLDGBX:XB	BBG00K2PDF45
FOLDGBX:XH	BBG00K2PDF63
FOLDGBX:XF	BBG00K2PDF81
FOLDGBX:XE	BBG00K2PDFB7
FOLDGBX:XJ	BBG00K2PDFC6
FOLDGBX:XL	BBG00K2PDFD5
FOLDGBX:XG	BBG00K2PDFF3
FOLDGBX:XO	BBG00K2PDFG2
FOLDGBX:XS	BBG00K2PDFL6
FOLDGBX:XA	BBG00K2PDFM5
FOLDGBX:E1	BBG00K2PDFN4
FOLDGBX:XT	BBG00K2PDFP2
FOLDGBX:XW	BBG00K2PDFQ1
FOLDGBX:XU	BBG00K2PDFR0
FOLDGBX:XV	BBG00K2PDFS9
FOLDGBX:XM	BBG00K2PDFT8
FOLDGBX:XQ	BBG00K2PDFW4
FOLDGBX:XX	BBG00K2PDFX3
FOLDGBX:XZ	BBG00K2PDFY2
FOLDGBX:EU	BBG00K2PDG07
FOLD:VG	BBG00X1NRHG1
FOLD:VP	BBG00X1S60H9
0HF9L:L1	BBG00Y7B36X0
AM6:GZ	BBG00Z0WX0K2
FOLD-RM:RM	BBG014BTY257
FOLD-RM:RX	BBG014BTY266
FOLD-RM:RN	BBG014BTY275
FOLD-RM:RP	BBG014BTY284
AM6:LA	BBG018H8BR49
AM6:LU	BBG018J1ZTQ8

Napravi najbolje investicije svog života.

Cena

Cena

ТикерFOLD

ISINUS03152W1099

WKNA0MSMZ

Amicus Therapeutics Cena akcije

Kurs

Pregled

Intraday funkcija

Ukupan prinos i relativna promena cene

Interpretacija i investiranje

Amicus Therapeutics Istorija kursa

Amicus Therapeutics Akcija Promet, EBIT, Dobit US03152W1099 · A0MSMZ

Promet, Profit & EBIT

Razumevanje prometa, EBIT-a i prihoda

Godišnja analiza i poređenja

Koristite očekivanja za investiranje

Uvid u investicije

Amicus Therapeutics Prihod, dobit i EBIT istorija

Amicus Therapeutics Akcija Kennzahlen

GuV

Prihod i rast

Bruto marža

EBIT i EBIT marža

Prihod i rast

Izdate akcije

Interpretacija godišnje usporedbe

Očekivanja i prognoze

Bilans

Razumevanje bilansa

Sredstva

Obaveze

Kapital

Analiza iz godine u godinu

Interpretacija podataka

Amicus Therapeutics Акција Маргине US03152W1099 · A0MSMZ

Margine

Razumevanje bruto marže

Analiza marže EBIT

Uvidi u maržu obrta

Tumačenje očekivanja

Analiza poređenja

Amicus Therapeutics Istorija margine

Amicus Therapeutics акција промет, EBIT, добит по акцији US03152W1099 · A0MSMZ

Promet, EBIT i Zarada po deonici

Promet po deonici

EBIT po deonici

Prihod po deonici

Očekivane vrednosti

Amicus Therapeutics Promet, dobit i EBIT po akciji - istorija

Amicus Therapeutics Akcija i analiza akcija

Amicus Therapeutics Prihod po regionu US03152W1099 · A0MSMZ

Prihod po segmentima

Pregled prihoda po regionu

Interpretacija i korišćenje

Investiciona strategija

Amicus Therapeutics Prihod po segmentu

Napravi najbolje investicije svog života

Amicus Therapeutics Оцена према Fair Value

Fair Value

Razumevanje Fair Value

Fair Value zasnovan na dobitku

Fair Value zasnovan na prihodu

Fair Value zasnovan na dividendi

Očekivanja i prognoze

Uporedna analiza

Amicus Therapeutics Ocena na osnovu istorijskog KGV, EBIT i KUV

Napravi najbolje investicije svog života

Amicus Therapeutics Broj akcija US03152W1099 · A0MSMZ

Promet, EBIT i Zarada po deonici

Promet po deonici

EBIT po deonici

Prihod po deonici

Očekivane vrednosti

Napravi najbolje investicije svog života

Amicus Therapeutics Procene zarade

Amicus Therapeutics Iznenađenja u zaradi

Eulerpool ESG ocena za akciju Amicus Therapeutics

Eulerpool World ESG Rating (EESG©)

Тикер
FOLD

ISIN
US03152W1099

WKN
A0MSMZ